A Parallel Phase I/II Clinical Trial Design for Combination Therapies
DOI10.1111/J.1541-0420.2006.00685.XzbMATH Open1137.62396OpenAlexW2006862074WikidataQ51908327 ScholiaQ51908327MaRDI QIDQ5459586FDOQ5459586
Authors: Xuelin Huang, Swati Biswas, Yasuhiro Oki, Jean-Pierre Issa, Donald A. Berry 
Publication date: 29 April 2008
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.1541-0420.2006.00685.x
Recommendations
- A three-stage Bayesian adaptive phase I/II design and simulation studies
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- Bayesian designs for phase I--II clinical trials
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Cites Work
- The Randomized Play-the-Winner Rule in Medical Trials
- Bayesian statistics and the efficiency and ethics of clinical trials
- Design and Analysis of Phase I Clinical Trials
- Designs for Single- or Multiple-Agent Phase I Trials
- Dose-finding with two agents in phase I oncology trials
- Two‐Dimensional Dose Finding in Discrete Dose Space
- Seamlessly expanding a randomized phase II trial to phase III
Cited In (11)
- A multi‐source adaptive platform design for testing sequential combinatorial therapeutic strategies
- A Bayesian phase I/II trial design for immunotherapy
- Making Efficient Use of Patients in Designing Phase III Trials Investigating Simultaneously a Set of Targeted Therapies with Different Targets
- A three-stage Bayesian adaptive phase I/II design and simulation studies
- Continual reassessment method for partial ordering
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- A prospective combination of phase II and phase III in drug development
- Phase 2 and 3 Combination Designs to Accelerate Drug Development
- Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
This page was built for publication: A Parallel Phase I/II Clinical Trial Design for Combination Therapies
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5459586)
